UNSPSC 51271629: Lidocaine hydrochloride

This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V13007Z41A. European Medicines Agency schedules Lidocaine hcl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02921MIG. Lidocaine hydrochloride generally arises in the molecular formula C14H22N2O.CLH.H2O. The term 'lidocaine hydrochloride' is an International Nomenclature of Cosmetic Ingredients designation.

Most nations, for tariff and trade purposes, schedule lidocaine hydrochloride under HS 29242910 and SITC 51479. As of Q4 2014, LIDOCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lidocaine hydrochloride bears US NLM identifiers UMLS ID C0546869 and NCI Concept Code C48000. SMILES: CCN(CC)CC(=O)NC1C(CCCC1C)C.O.CL.

UNSPSC 51271629 Lidocaine hydrochloride is a Commodity-tier code for the direct procurement of lidocaine hydrochloride, a local anesthetic and antiarrhythmic pharmaceutical product used across state and local health systems, emergency services, and correctional facilities. State and local governments purchase lidocaine hydrochloride in multiple formulations — injectable solutions, topical preparations, and intravenous admixtures — for use in emergency departments, operating rooms, dental clinics, wound care, and cardiac response protocols. Issuing bodies include state health departments, state prison systems, county hospitals and health authorities, municipal fire and rescue departments, and independent school districts operating health clinics. The commodity sees procurement activity across healthcare purchasing cooperatives and direct solicitations from individual agencies.

The source provides no recent state and local contract opportunities tagged to this code; the lack of posted activity does not indicate absence of procurement volume, as pharmaceutical commodities are frequently purchased through standing cooperative agreements, blanket purchase orders, and master vendor contracts that may not generate discrete RFP or RFQ notices. When state and local agencies do solicit lidocaine hydrochloride competitively, they typically issue RFQ or IFB notices with response cycles of one to four weeks, often as part of broader pharmaceutical supply schedules or emergency medical supply awards. Geographic activity spans all states with significant healthcare infrastructure and emergency services, though specific recent posting data is not available in the source to identify concentration in particular regions or repeat-buyer patterns.